Patent “use” claims for ACLASTA held to be directed to methods of medical treatment and hence unpatentable
Plaintiff World Medicine İlaç San. And Ve Aş. won the case against Novartis to invalidate the patents of TR 2005/04747 and TR 2011/06480 of ACLASTA (zoledronic acid) medicines becase of the claims are not novel and does not have inventive steps . Moreeover the claims are method of traatment. The court also rejected Novartis 's claims for detectng, preventing the infiringement from patent rights. the rape. Plaintiff providing information about the subject World Medicine İlaç San. Ve Tic. AŞ 's attorney and founding partner of Avrupa Patent Ofisi ; Av. Yağmur Kutlucan said that Novartis lawyers appealead the courts decision.
LATEST NEWS
- ANKARA INTELLECTUAL PROPERTY AND RIGHTS COURT REJECTED THE SUIT OF MIGROS FOR INVALIDATION OF MAKRO TRADEMARK BELONG TO MAKRO TEKNIK
- LUKOIL TRADEMARK IS REGISTERED AS A WELL KNOWN TRADEMARK IN TURKISH PATENT AND TRADE AGENCY.
- İYİ PARTY WILL BE SUITED FOR THE REGISTERED BRAND IN THE NAME OF BİLECİK MUNICIPALITY
- AVRUPA PATENT BÜROSU is the 2nd TRADEMARK ATTORNEY IN TURKEY THAT MADE MOST INTERNATIONAL TRADEMARK APPLICATION WITH THE MADRID SYSTEM.
- THE TRADEMARK ATTORNEY OF THE APPLICANTS WHICH MADE THE MOST INTERNATIONAL TRADEMARK APPLICATION IN TURKEY IS AVRUPA PATENT BÜROSU
